These findings suggest a novel therapeutic application of SGLT2 inhibitors for managing intractable hypomagnesemia, both acutely and chronically, regardless of the diabetes being the primary culprit. This evidence concerns the gene SLC5A2 and familial primary hypomagnesemia.